OncLive Fellows Forum | Conference

ICI Use Does Not Significantly Affect EOL Outcomes in HCC

October 29th 2025

Margaret Wheless, MD, discusses findings from a study of end-of-life outcomes and health care resource utilization in ICI-treated HCC.

OncLive Fellows Forum Spotlights New Data for Tarlatamab in SCLC and PRO Results in Hospitalized Patients

September 13th 2025

Kelsey Pan, MD, MPH, discusses notable presentations from an OncLive Fellows Forum on Thoracic Oncology.

Thoracic Oncology Fellows Forum Is Highlighted by PRO Data and Tarlatamab in SCLC

August 18th 2025

Hematology/oncology fellows shared insights on notable presentations given during the OncLive Fellows Forum on Thoracic Oncology.

Dr Azenkot on Dupilumab Plus Cemiplimab in Early-Stage, Resectable NSCLC

July 7th 2025

Tali Azenkot, MD, discusses the rationale for combining dupilumab with cemiplimab in early-stage, resectable non–small cell lung cancer.

Dr Jeon on Research Presented at an OncLive Lung Cancer Fellows Forum

July 7th 2025

Hyein Jeon, MD, highlights key abstracts and takeaways from an OncLive Fellows Forum on lung cancer.

Low KIM-1 Levels Are Associated With Improved Clinical Outcomes in Advanced RCC

July 2nd 2025

A research fellow from Dana-Farber Cancer Institute shares post hoc findings from the phase 3 JAVELIN Renal 101 trial.

Dr Jani on the Inclusion of PRO End Points in Lung Cancer Clinical Trials

July 1st 2025

Chinmay Jani, MD, discusses the rate of inclusion of patient-reported outcome end points in clinical trials of patients with lung cancer.

Dr Soror on Patient-Reported Outcomes in Hospitalized Patients With Cancer

June 30th 2025

Noha Soror, MD, discussed data from an analysis of patient-reported outcomes in from hospitalized patients with cancer.

Dr Cameron on the Prognostic Value of PD-L1 for Outcomes With Osimertinib in EGFR+ NSCLC

June 24th 2025

Robert Cameron, MD, PhD, discusses a study examining the impact of PD-L1 expression on outcomes with osimertinib in EGFR-mutated NSCLC.

Dr Parma on Survival Outcomes With Immunotherapy in Patients With NSCLC Brain Metastases

June 23rd 2025

Mitchell Parma, MD, discusses an analysis of survival benefit with immunotherapy in patients with NSCLC brain metastases.

Dr Pan on the Real-World Utilization of Tarlatamab in Patients With SCLC

June 19th 2025

Kelsey Pan, MD, MPH, highlights the utilization of tarlatamab in real-world patients with SCLC ineligible for the phase 2 DeLLphi-301 trial.

Fellows Present Their Findings on the Breast Cancer Immune Microenvironment and Telehealth Delivery at National Fellows Forum

March 26th 2025

Tess O’Meara, MD, MHS, and Kelsey H. Natsuhara, MD, discuss their presentations from the OncLive National Fellows Forum at SABCS.

National Fellows Forum Showcases Next Generation of Lung Cancer Clinicians

October 20th 2024

Oncology fellows with aspirations of entering the lung cancer field gathered in Chicago, Illinois, to share findings from their research, network, and participate in panel discussions featuring expert faculty